Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Cost-effectiveness analysis of mosunetuzumab compared with novel alternative immunotherapies in patients with third-line or later relapsed/refractory follicular lymphoma in Japan

Ritsuro Suzuki, Hiroyuki Sakamaki, Naoki Inubashiri et al. Nov 03, 2025 pp. 6178-6178 10.1182/blood-2025-6178

Abstract INTRODUCTION Follicular lymphoma (FL), a common indolent non-Hodgkin's lymphoma (NHL), accounts for approximately 10-20% of all NHLs...

Integrative omics analysis of TP53 in multiple myeloma patients

Cristina De Ramón Sánchez, Elizabeta A Rojas, Irena Misieweicz et al. Nov 03, 2025 pp. 2162-2162 10.1182/blood-2025-2162

Abstract Introduction: Although TP53 gene alterations—such as 17p deletion and TP53 mutations—occur at relatively low fr...

Early life anthropometrics predict anthropometrics later in children with sickle cell disease and are different from the general population

Chinenye Dike, Jeremiah Tella, Amy Fan et al. Nov 03, 2025 pp. 1163-1163 10.1182/blood-2025-1163

Abstract Background: There is conflicting data on the effects of sickle cell disease (SCD) on anthropometrics. While some studies report tha...

FCR-I/iven combination for CLL: «Cheap but fierce»

Vitaly Dubov, Eugene Zvonkov, Daria Koroleva et al. Nov 03, 2025 pp. 7425-7425 10.1182/blood-2025-7425

Abstract Introduction. In the CLL8 trial for treatment-naïve patients with CLL, the FCR group had a PFS of 56.8 months compared with 32.9 mo...

Real-world study of population pharmacokinetic-guided pdVWF/FVIII (1:1) prophylaxis in people with severe von Willebrand disease: The PopPK-WILPROPHY study

Robert Sidonio, Jr., Ron Mathôt Nov 03, 2025 pp. 4856-4856 10.1182/blood-2025-4856

Abstract Introduction: Prophylaxis with a von Willebrand factor (VWF)-containing concentrate is recommended for individuals with von Willebr...

Maternal and fetal pharmacokinetics (PK) of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH): A case report of use in pregnancy

Benjamin Chin-Yee, Benjamin Hedley, Rui Su et al. Nov 03, 2025 pp. 3199-3199 10.1182/blood-2025-3199

Abstract Background: PNH is a rare, life-threatening hematologic disorder that poses significant risks in pregnancy. Pegcetacoplan, a first-i...

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study

Meghan Thompson, Annamaria Frustaci, John Seymour et al. Nov 03, 2025 pp. 3895-3895 10.1182/blood-2025-3895

Abstract Introduction: There is no standard of care treatment for Richter transformation (RT) of chronic lymphocytic leukemia/small lymphocyt...

Relapsed/Refractory Hodgkin lymphoma after first-line escalated beacopdac: Adverse outcomes are overcome by use of second-line targeted therapy - an international real-world analysis

Lisa Jeffers, Anna Santarsieri, Wendy Osborne et al. Nov 03, 2025 pp. 3623-3623 10.1182/blood-2025-3623

Abstract Introduction Escalated (e) BEACOPP is a well-established treatment option for advanced and intermediate-stage Hodgkin Lymphoma (HL)....

Evaluating the risk of non-melanoma skin cancer in patients with porphyria cutanea tarda: A retrospective cohort study using real-world data

Ruhi Kanwar, Thomas Rohan, Vinod Nambudiri Nov 03, 2025 pp. 6232-6232 10.1182/blood-2025-6232

Abstract Porphyrias are a group of disorders caused by disruptions in heme biosynthesis, each leading to accumulation of distinct porphyrin...

Trials in progress - a Phase Ib trial of epcoritamab in combination with ibrutinib in relapsed or refractory central nervous system lymphoma (EIFEL)

Narendranath Epperla, Allison Bock, Boyu Hu et al. Nov 03, 2025 pp. 1972-1972 10.1182/blood-2025-1972

Abstract Background: Primary central nervous system lymphomas (PCNSL) is an aggressive subtype of diffuse large B-cell lymphoma with poor ou...

Letermovir primary prophylaxis is associated with reduced and delayed CMV reactivation in haploidentical allohct using ptcy.

Felipe Peña-Muñoz, Fernando Molina, Marta Peña et al. Nov 03, 2025 pp. 7711-7711 10.1182/blood-2025-7711

Abstract Background: The use of letermovir (LTV) in the allogeneic hematopoietic cell transplant has dramatically changed the incidence of c...

Endothelial activation and stress index EASIX and it's variants as a prognostic marker for cytokine release syndrome in CAR-T cell therapy recipients: A systematic review and meta analysis

Anas nasir, Ahmed Raza, Muhammad Rafay Paracha et al. Nov 03, 2025 pp. 7234-7234 10.1182/blood-2025-7234

Abstract INTRODUCTION Background: Chimeric antigen receptor (CAR) T-cell therapy, while being efficacious for haematological malignancies, is...

Comparable efficacy of CR, CRh, and CRi in pediatric acute myeloid leukemia: A report from the Japan Children's Cancer Group

Shota Kato, Jun Matsubayashi, Rina Nojima et al. Nov 03, 2025 pp. 3512-3512 10.1182/blood-2025-3512

Abstract Introduction: The 2022 European Leukemia Network (ELN) recommendations defined several efficacy endpoints for acute myeloid leukemi...

Impact of adenovirus infection on the long-term cardiovascular and other outcomes following CAR T-cell therapy: A propensity-matched cohort study

Aakriti Adhikari, Abat Khan, Abdul Wali Khan et al. Nov 03, 2025 pp. 7683-7683 10.1182/blood-2025-7683

Abstract Background: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematologic malignancies but is asso...

Gender disparities in first-author representation across ASH submissions 2019-2024

Bret Miller, Taha Huda, Cole Miller et al. Nov 03, 2025 pp. 8222-8222 10.1182/blood-2025-8222

Abstract Background: Achieving gender equity in academic hematology requires a multifaceted approach across all presentation types and resea...

Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial

María-Victoria Mateos, Pawel Robak, Marek Hus et al. Nov 03, 2025 pp. 2265-2265 10.1182/blood-2025-2265

Abstract Introduction: In the phase 3 DREAMM-7 trial (NCT04246047), belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) d...

Benchmark evaluation of large language models in acute myeloid leukemia prognosis

Xiangjie Lin, Di Xu, Nanfang Zhuo et al. Nov 03, 2025 pp. 7954-7954 10.1182/blood-2025-7954

Abstract Background: Acute myeloid leukemia (AML) is a highly heterogeneous malignancy requiring accurate prediction of treatment response a...

CD19 expression is preserved following CD19-directed monoclonal antibody therapy with tafasitamab

Johannes Duell, Diana Alvarez Arias, Wolfram Klapper et al. Nov 03, 2025 pp. 5515-5515 10.1182/blood-2025-5515

Abstract Background: The availability of multiple CD19-targeted agents of different drug classes allows for sequential targeting of the CD19...

Effect of exercise on body composition and bone health in patients with thalassemia

Ellen Fung, Raquel Manzo, Emily Van Horn et al. Nov 03, 2025 pp. 8228-8228 10.1182/blood-2025-8228

Abstract Study Rationale: Over half of all adults with thalassemia (Thal) have low bone mass, bone pain and are at significant risk for frac...

Non-response to rituximab during immune thrombocytopenia is associated with more differentiated circulating B cells and CD8 T cells

Roman Praliaud, Baptiste Lamarthée, Alexis Varin et al. Nov 03, 2025 pp. 1248-1248 10.1182/blood-2025-1248

Abstract Introduction. Immune thrombocytopenia (ITP) is a rare, acquired autoimmune disorder characterized by isolated thrombocytopenia with...

Real-world comparison of CAR T-cell therapy versus bispecific antibodies in relapsed or refractory multiple myeloma

Jia Yi Tan, Aravinthan Vignarajah, Nurliyanah Atiqah et al. Nov 03, 2025 pp. 2799-2799 10.1182/blood-2025-2799

Abstract Introduction Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies have emerged as transformative options for pa...

A novel reduce toxity myeloablative conditioning regimen f-BMT improves efficacy and safety of allogeneic hematopoietic stem cell transplantation in patients with transfusion-dependent thalassemia: A multicenter clinical trial

Guiping Liao, Dongmei Liu, Yali Zhou et al. Nov 03, 2025 pp. 729-729 10.1182/blood-2025-729

Abstract Background Conditioning regimens are crucial in allogeneic hematopoietic stem cell transplantation (allo-HSCT), especially for olde...

Trial in progress: Efficacy and safety of givinostat versus hydroxyurea in patients with polycythemia vera (GIV-IN-PV)

Alessandro Rambaldi, John Mascarenhas, Paolo Bettica et al. Nov 03, 2025 pp. 3828-3828 10.1182/blood-2025-3828

Abstract Background: Polycythemia vera (PV) is a BCR-ABL1-negative myeloproliferative neoplasm (MPN) characterized by excessive proliferation...

Exploring the immunodynamic landscape of blinatumomab therapy in pediatric BCP-ALL through full-spectrum flow cytometry

Mingying Zhang, Wei Lin, Ying Wu et al. Nov 03, 2025 pp. 1597-1597 10.1182/blood-2025-1597

Abstract Background B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common malignancy in children. Blinatumomab is a bis...

PTP4A3: A potential therapeutic target in Acute Myeloid Leukemia

Changqing Jiao, Junjie Zhou, Yan Zhang et al. Nov 03, 2025 pp. 1460-1460 10.1182/blood-2025-1460

Abstract Protein tyrosine phosphatase 4A3 (PTP4A3), a member of the protein tyrosine phosphatase family, regulates intracellular signaling b...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page